AlphAIAlphAI — Financial news for AI agents
finanznachrichten.deSEP 182 min read$INM

InMed Pharmaceuticals: InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Shareholders' Equity Compliance

InMed Pharmaceuticals (NASDAQ: INM) received a Nasdaq notification for failing to meet the minimum shareholders' equity requirement of $2.5M, reporting $1.075M. The company attributes this to merger-related expenses and other costs. InMed expects to regain compliance post-merger with Mentari Therapeutics, anticipating $490M in gross proceeds. The company has 45 days to submit a compliance plan and may receive a 180-day extension. The merger is expected to close in Q4 2026, subject to shareholder

Original reporting
finanznachrichten.de
Published Sep 18, 2026, 9:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 18, 2026, 9:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefCorporate actions
Primary signal
$INM
Bearish
high confidence
Mentioned
$INM
Relevance
6/10
AlphAI data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$INMBearishMed
01

Why it matters

The compliance notice creates short-term risk, but the pending merger could resolve the issue.

02

Market read

Compliance risk may trigger a sell-off, but merger proceeds could offset the downside.

03

What to watch

Potential for a Nasdaq extension and appeal process may mitigate immediate price impact.

Relevance 6/10Novelty 7/10Timing: today

Background

InMed Pharmaceuticals is merging with Mentari Therapeutics, which is expected to provide $490M in proceeds to restore equity compliance.

Company-level read

Ticker impact

$INMBearishHigh confidence
Context

Nasdaq notified InMed Pharmaceuticals that its shareholders' equity fell below the $2.5M minimum, threatening delisting unless compliance is regained.

Expected impact

Downside pressure until equity compliance is demonstrated or merger completes.

Evidence & confidence

Equity shortfall is material for a Nasdaq-listed company and may trigger a sell-off.

Market effects

Sector

Highlights compliance risk for small-cap biotech firms on Nasdaq.

Regional

May affect investor sentiment toward Canadian biotech listings.

Global

Limited to Nasdaq-listed biotech sector.

Counterpoint

What could challenge this read

If the merger with Mentari closes as planned, equity will be restored and the stock could rebound.

Key entities

  • Company
    InMed Pharmaceuticals Inc.

    Nasdaq-listed biotech facing equity compliance shortfall.

  • Company
    Mentari Therapeutics, Inc.

    Merger partner providing financing to restore equity.

Read at source← All news

Related articles

OCT 27
$INMMed

InMed Pharmaceuticals: InMed Announces CVR Distribution Record Date in Connection with Proposed Merger

InMed Pharmaceuticals (NASDAQ: INM) set November 5, 2026, as the record date for distributing contingent value rights (CVRs) to shareholders, pending approval of the merger with Mentari Therapeutics and shareholder approval of the Return of Capital Proposal at the November 4, 2026, meeting. The CVRs will be issued under a CVR Agreement, with each shareholder receiving one CVR per common share held as of the record date, but no CVRs will be issued for shares from stock options.

finanznachrichten.de1 min
SEP 18
$INMMed

InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Stockholders’ Equity Compliance

InMed Pharmaceuticals Inc. (INM) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Nasdaq: INM c/o Norton Rose Fulbright Canada LLP Suite 1800-510 West Georgia St. Vancouver, BC, Canada V6B 0M3 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Stockholders’ Equi

SEC EDGAR 8-K2 min
SEP 9
$INMMed

InMed Pharmaceuticals: InMed Reports Full Year Fiscal 2026 Financial Results and Provides Corporate Update

InMed Pharmaceuticals (INM) reported a net loss of $12.9M for FY2026, up from $8.2M in FY2025. The company is pursuing a merger with Mentari Therapeutics, expected to close by year-end, with Mentari raising $490M in pre-closing financing. InMed's legacy programs, including INM-901, INM-089, and INM-755, are being pursued for strategic opportunities. The company had $2.2M in cash as of June 30, 2026.

finanznachrichten.de2 min
JUL 22
$INMMed

InMed Pharmaceuticals Merger Partner Raises $200 Million To Boost Migraine Pipeline - InMed Pharmaceutica

Mentari Therapeutics raised an additional $200 million via a private placement ahead of its planned merger with InMed Pharmaceuticals (NASDAQ:INM). The deal also closes alongside a previously announced $290 million private placement. Funds extend Mentari’s cash runway into 2029 to support Phase 2a readouts for PACAP-targeted programs, including MT-002. Post-merger, the company will trade on Nasdaq under a new ticker.

benzinga.com4 min
JUL 6
$INMMed

InMed Pharmaceuticals: InMed Pharmaceuticals and Mentari Therapeutics Announce Amendment to Merger Agreement and Filing of Registration Statement on Form S-4

InMed Pharmaceuticals (NASDAQ: INM) said it amended a previously announced all-stock merger agreement with privately held Mentari Therapeutics and its merger subsidiaries. InMed filed a preliminary Form S-4 with the SEC for the deal. The boards approved; closing is expected in Q4 2026, pending shareholder approvals and S-4 effectiveness.

finanznachrichten.de3 min